Loading...

Generex Biotechnology

BST:GB8A
Snowflake Description

Slightly overvalued with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GB8A
BST
$77M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Generex Biotechnology has significant price volatility in the past 3 months.
GB8A Share Price and Events
7 Day Returns
-3.8%
BST:GB8A
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
943.9%
BST:GB8A
-10.2%
DE Biotechs
-6%
DE Market
GB8A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Generex Biotechnology (GB8A) -3.8% -14.8% -45.3% 943.9% 329809.9% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • GB8A outperformed the Biotechs industry which returned -10.2% over the past year.
  • GB8A outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
GB8A
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Generex Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Generex Biotechnology. This is due to cash flow or dividend data being unavailable. The share price is €1.0986.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Generex Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Generex Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:GB8A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $0.82
OTCPK:GNBT Share Price ** OTCPK (2019-04-18) in USD $1.29
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Generex Biotechnology.

BST:GB8A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:GNBT Share Price ÷ EPS (both in USD)

= 1.29 ÷ 0.82

1.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Generex Biotechnology is good value based on earnings compared to the Europe Biotechs industry average.
  • Generex Biotechnology is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Generex Biotechnology's expected growth come at a high price?
Raw Data
BST:GB8A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Generex Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Generex Biotechnology's assets?
Raw Data
BST:GB8A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $-0.25
OTCPK:GNBT Share Price * OTCPK (2019-04-18) in USD $1.29
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:GB8A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:GNBT Share Price ÷ Book Value per Share (both in USD)

= 1.29 ÷ -0.25

-5.13x

* Primary Listing of Generex Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Generex Biotechnology has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Generex Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Generex Biotechnology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Generex Biotechnology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Generex Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Generex Biotechnology expected to grow at an attractive rate?
  • Unable to compare Generex Biotechnology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Generex Biotechnology's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Generex Biotechnology's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:GB8A Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:GB8A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:GB8A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 5 -5 24
2018-10-31 2 -2 25
2018-07-31 1 -2 36
2018-04-30 1 -2 9
2018-01-31 1 -2 -37
2017-10-31 0 -2 -43
2017-07-31 -1 -70
2017-04-30 -1 -60
2017-01-31 0 -17
2016-10-31 0 -1
2016-07-31 -1 -3
2016-04-30 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Generex Biotechnology is high growth as no earnings estimate data is available.
  • Unable to determine if Generex Biotechnology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:GB8A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Generex Biotechnology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:GB8A Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 0.82
2018-10-31 0.95
2018-07-31 1.62
2018-04-30 0.39
2018-01-31 -1.65
2017-10-31 -1.99
2017-07-31 -3.38
2017-04-30 -3.03
2017-01-31 -0.88
2016-10-31 -0.05
2016-07-31 -0.18
2016-04-30 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Generex Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of GB8A’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Generex Biotechnology's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Generex Biotechnology's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Generex Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Generex Biotechnology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Generex Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Generex Biotechnology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Generex Biotechnology's year on year earnings growth rate has been positive over the past 5 years.
  • Generex Biotechnology has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Generex Biotechnology has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Generex Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Generex Biotechnology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:GB8A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 5.16 24.19 10.01 1.44
2018-10-31 2.42 24.69 4.23 0.78
2018-07-31 0.70 36.33 2.36 0.84
2018-04-30 0.70 8.71 2.39 0.85
2018-01-31 0.70 -36.91 2.05 0.74
2017-10-31 0.00 -42.93 1.47 0.66
2017-07-31 -70.02 1.17 0.42
2017-04-30 -59.65 0.72 0.41
2017-01-31 -16.64 0.45 0.30
2016-10-31 -0.93 0.40 0.29
2016-07-31 -3.22 1.44 0.47
2016-04-30 -1.53 1.94 0.65
2016-01-31 -3.85 2.49 0.80
2015-10-31 -4.31 3.35 0.95
2015-07-31 -2.53 2.38 1.19
2015-04-30 0.30 2.16 1.14
2015-01-31 0.54 2.43 1.26
2014-10-31 -2.54 2.28 1.26
2014-07-31 -2.06 3.02 1.38
2014-04-30 -9.39 3.50 1.66
2014-01-31 -6.94 3.56 1.79
2013-10-31 -8.99 3.56 2.08
2013-07-31 -10.28 3.94 2.19
2013-04-30 0.01 -6.68 4.19 2.34
2013-01-31 0.01 -7.48 4.58 2.99
2012-10-31 0.02 -10.96 4.84 3.22
2012-07-31 0.03 -9.87 5.05 4.55
2012-04-30 0.04 -14.50 7.25 6.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Generex Biotechnology made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Generex Biotechnology used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Generex Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Generex Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Generex Biotechnology has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Generex Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Generex Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Generex Biotechnology's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Generex Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Generex Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Generex Biotechnology Company Filings, last reported 2 months ago.

BST:GB8A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 10.57 43.34 2.37
2018-10-31 -25.60 29.72 2.36
2018-07-31 -43.58 14.18 1.05
2018-04-30 -58.52 14.20 1.57
2018-01-31 -62.06 14.18 2.05
2017-10-31 -52.34 13.91 2.34
2017-07-31 -79.88 13.74 2.88
2017-04-30 -67.46 14.12 0.04
2017-01-31 -23.66 14.10 0.08
2016-10-31 -10.65 0.05 0.01
2016-07-31 -11.22 0.05 0.02
2016-04-30 -8.88 0.00 0.05
2016-01-31 -9.80 0.00 0.03
2015-10-31 -9.88 0.00 0.05
2015-07-31 -8.29 0.00 0.75
2015-04-30 -7.72 0.00 0.93
2015-01-31 -6.40 0.00 1.61
2014-10-31 -5.96 0.00 2.22
2014-07-31 -6.09 0.00 3.27
2014-04-30 -8.46 0.00 4.22
2014-01-31 -8.08 0.00 3.14
2013-10-31 -8.91 0.00 1.03
2013-07-31 -10.14 0.62 1.71
2013-04-30 -8.10 0.63 0.41
2013-01-31 -10.89 0.85 1.12
2012-10-31 -8.38 1.66 0.25
2012-07-31 -8.38 1.66 0.25
2012-04-30 -7.65 2.05 1.19
  • Generex Biotechnology's level of debt (410%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 410% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Generex Biotechnology's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Generex Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Generex Biotechnology has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Generex Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Generex Biotechnology dividends.
If you bought €2,000 of Generex Biotechnology shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Generex Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Generex Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:GB8A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Generex Biotechnology has not reported any payouts.
  • Unable to verify if Generex Biotechnology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Generex Biotechnology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Generex Biotechnology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Generex Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Generex Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Generex Biotechnology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Generex Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Moscato
COMPENSATION $100,000
AGE 54
TENURE AS CEO 2.3 years
CEO Bio

Mr. Joseph Moscato, also known as Joe, has been the Chief Executive Officer, President and Director of Generex Biotechnology Corporation since January 18, 2017 and serves as its Chairman of the Board. Since 2009, Mr. Moscato has been an Exclusive Consultant to Generex Biotechnology Corp. He has over 30 years of experience in healthcare, sales and marketing, distribution management and finance. He has his marketing and advertising acumen to drug discovery, diagnostic and treatment development and commercialization. He has originated and negotiated several licensing deals with the top biopharmaceutical companies; has advised in the equity financing totaling over $300 million; and has implemented the broad strategic vision for the company. Mr. Moscato has worked and consulted for Pfizer in several capacities from sales and marketing to new drug discovery & development for licensing. He has worked with other biopharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson, Parke-Davis, Amgen and others. He has consulted for several healthcare focused private equity, hedge funds and family offices. He also owned several advertising and marketing agencies focused on media, entertainment and healthcare with clients ranging from Motorola, Chadmoore Wireless, Nextel, Cannon, Sharp, GlaxoSmithKline, Pfizer and other biopharmaceutical companies. Mr. Moscato’s agency was acquired by William Douglas McAdams, one of the largest independent healthcare advertising and marketing agencies.

CEO Compensation
  • Joe's compensation has increased in line with Generex Biotechnology recently becoming profitable.
  • Joe's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Generex Biotechnology management team in years:

2.3
Average Tenure
55.5
Average Age
  • The tenure for the Generex Biotechnology management team is about average.
Management Team

Joe Moscato

TITLE
Chairman
COMPENSATION
$100K
AGE
54
TENURE
2.3 yrs

Joseph Corrao

TITLE
CFO & Treasurer
COMPENSATION
$40K
AGE
63

Andrew Ro

TITLE
Chief Investment Officer & Director
COMPENSATION
$25K
AGE
47
TENURE
2.3 yrs

Rich Purcell

TITLE
Senior Vice President of Research & Drug Development
COMPENSATION
$68K
AGE
57
TENURE
2.3 yrs

Terry Thompson

TITLE
Chief Operating Officer
AGE
60
TENURE
0.8 yrs

Dick Suedkamp

TITLE
Executive Vice President of Finance & Accounting

Jason Terrell

TITLE
Chief Scientific Officer & Chief Medical Officer
AGE
38
TENURE
2.3 yrs

Marshal Schictman

TITLE
Executive VP & General Counsel
TENURE
0.2 yrs

Steve Worster

TITLE
Chief Compliance Officer

Michelle Starr

TITLE
Chief Marketing Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Generex Biotechnology board of directors in years:

2.3
Average Tenure
54
Average Age
  • The average tenure for the Generex Biotechnology board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joe Moscato

TITLE
Chairman
COMPENSATION
$100K
AGE
54
TENURE
2.3 yrs

Andrew Ro

TITLE
Chief Investment Officer & Director
COMPENSATION
$25K
AGE
47
TENURE
2.3 yrs

Brian McGee

TITLE
Independent Director
AGE
53
TENURE
15.1 yrs

Gerald Bernstein

TITLE
Member of Scientific Advisory Board
COMPENSATION
$230K
AGE
85
TENURE
18.3 yrs

Craig Eagle

TITLE
Independent Director
AGE
51
TENURE
2.3 yrs

James Anderson

TITLE
Independent Director
AGE
69
TENURE
7.8 yrs

Lawrence Salvo

TITLE
Director
AGE
66
TENURE
2.3 yrs

Omar Gzouli

TITLE
Independent Interim Director

Mark Prioletti

TITLE
Independent Interim Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Dec 18 Buy Harold Haines Individual 04. Dec 18 07. Dec 18 9,800 €1.86 €10,422
X
Management checks
We assess Generex Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Generex Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.

Details
Name: Generex Biotechnology Corporation
GB8A
Exchange: BST
Founded: 1983
$68,625,479
60,362,143
Website: http://www.generex.com
Address: Generex Biotechnology Corporation
10102 USA Today Way,
Suite 200,
Miramar,
Florida, 33025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK GNBT Common Stock Pink Sheets LLC US USD 05. Feb 1998
BST GB8A Common Stock Boerse-Stuttgart DE EUR 05. Feb 1998
Number of employees
Current staff
Staff numbers
3
Generex Biotechnology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:51
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/04/16
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.